Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma.
Maehara O, Suda G, Natsuizaka M, Shigesawa T, Kanbe G, Kimura M, Sugiyama M, Mizokami M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohashi S, Kagawa S, Kinugasa H, Naganuma S, Okubo N, Ohnishi S, Takeda H, Sakamoto N. Maehara O, et al. Among authors: shigesawa t. Cancer Biol Ther. 2021 Jun 3;22(5-6):372-380. doi: 10.1080/15384047.2021.1939638. Epub 2021 Jul 5. Cancer Biol Ther. 2021. PMID: 34224333 Free PMC article.
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T, Maehara O, Suda G, Natsuizaka M, Kimura M, Shimazaki T, Yamamoto K, Yamada R, Kitagataya T, Nakamura A, Suzuki K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohnishi S, Sugiyama M, Mizokami M, Takeda H, Sakamoto N. Shigesawa T, et al. Carcinogenesis. 2021 Feb 11;42(1):58-69. doi: 10.1093/carcin/bgaa049. Carcinogenesis. 2021. PMID: 32449510
Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma.
Shigesawa T, Suda G, Kimura M, Shimazaki T, Maehara O, Yamada R, Kitagataya T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Shigesawa T, et al. JGH Open. 2020 Apr 11;4(5):880-888. doi: 10.1002/jgh3.12339. eCollection 2020 Oct. JGH Open. 2020. PMID: 33102759 Free PMC article.
Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
Shigesawa T, Suda G, Kimura M, Maehara O, Tokuchi Y, Kubo A, Yamada R, Furuya K, Baba M, Kitagataya T, Suzuki K, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Shigesawa T, et al. PLoS One. 2021 Mar 1;16(3):e0247728. doi: 10.1371/journal.pone.0247728. eCollection 2021. PLoS One. 2021. PMID: 33647018 Free PMC article.
Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
Sho T, Suda G, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Izumi T, Kawagishi N, Baba M, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Sho T, et al. Among authors: shigesawa t. Intern Med. 2019 Mar 15;58(6):797-802. doi: 10.2169/internalmedicine.1856-18. Epub 2018 Nov 19. Intern Med. 2019. PMID: 30449808 Free PMC article.
Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter.
Izumi T, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N. Izumi T, et al. Among authors: shigesawa t. Hepatol Res. 2019 Oct;49(10):1207-1217. doi: 10.1111/hepr.13391. Epub 2019 Jul 10. Hepatol Res. 2019. PMID: 31219667
Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis.
Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Kimura M, Maehara O, Shimazaki T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suzuki K, et al. Among authors: shigesawa t. Hepatol Res. 2019 Nov;49(11):1294-1304. doi: 10.1111/hepr.13399. Epub 2019 Jul 25. Hepatol Res. 2019. PMID: 31260579
Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs.
Suda G, Kimura M, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Maehara O, Shimazaki T, Morikawa K, Natsuizaka M, Ogawa K, Sakamoto N. Suda G, et al. Among authors: shigesawa t. Hepatol Res. 2019 Nov;49(11):1275-1285. doi: 10.1111/hepr.13401. Epub 2019 Jul 23. Hepatol Res. 2019. PMID: 31261439
High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C.
Kawagishi N, Suda G, Kimura M, Maehara O, Shimazaki T, Yamada R, Kitagataya T, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N. Kawagishi N, et al. Among authors: shigesawa t. Hepatol Res. 2020 Jun;50(6):671-681. doi: 10.1111/hepr.13490. Epub 2020 Feb 18. Hepatol Res. 2020. PMID: 32020702 Free article.
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
Sho T, Suda G, Ogawa K, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Yokoo H, Kamiyama T, Taketomi A, Sakamoto N. Sho T, et al. Among authors: shigesawa t. JGH Open. 2019 Jun 10;4(1):54-60. doi: 10.1002/jgh3.12209. eCollection 2020 Feb. JGH Open. 2019. PMID: 32055698 Free PMC article.
35 results